The effects of class-specific histone deacetylase inhibitors on the development of limbs during organogenesis

Toxicological Sciences

Volumn 148, Issue 1, 2015, Pages 220-228

  Paradis, France Hélène ^a   Hales, Barbara F ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

apoptosis; chondrogenesis; HDAC inhibitor; limb development; MC1568; MS275; osteogenesis; Sirtinol; teratogen; valproic acid

Indexed keywords

3 [4 [3 (3 FLUOROPHENYL) 3 OXO 1 PROPENYL] 1 METHYL 1H PYRROL 2 YL]ACRYLOHYDROXAMIC ACID; CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 10; COLLAGEN TYPE 10A1; COLLAGEN TYPE 1A1; COLLAGEN TYPE 2; COLLAGEN TYPE 2A1; CYAN FLUORESCENT PROTEIN; ENTINOSTAT; SIRTINOL; UNCLASSIFIED DRUG; VALPROIC ACID; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; COL10A1 PROTEIN, MOUSE; COL2A1 PROTEIN, MOUSE; COLLAGEN TYPE I, ALPHA 1 CHAIN; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; HYDROXAMIC ACID; NAPHTHOL DERIVATIVE; PHOTOPROTEIN; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; TERATOGENIC AGENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CARTILAGE CELL; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; IN VITRO STUDY; LIMB BUD; LIMB DEVELOPMENT; MOUSE; NONHUMAN; ORGANOGENESIS; OSTEOBLAST; PROTEIN EXPRESSION; ANIMAL; CELL CULTURE; CLASSIFICATION; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; FEMALE; FORELIMB; GENE EXPRESSION REGULATION; GENETICS; MAMMALIAN EMBRYO; METABOLISM; PATHOLOGY; PREGNANCY; REPORTER GENE; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; BENZAMIDES; BIOMARKERS; CELLS, CULTURED; CHONDROGENESIS; COLLAGEN TYPE I; COLLAGEN TYPE II; COLLAGEN TYPE X; EMBRYO, MAMMALIAN; FEMALE; FORELIMB; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENES, REPORTER; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; LUMINESCENT PROTEINS; MICE, TRANSGENIC; NAPHTHOLS; OSTEOGENESIS; PREGNANCY; PYRIDINES; PYRROLES; RECOMBINANT FUSION PROTEINS; TERATOGENS;

EID: 84944443150     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv174     Document Type: Article

References (39)

1. Banh, S., and Hales, B. F. (2013). Hydroxyurea exposure triggers tissue-specific activation of p38 mitogen-activated protein kinase signaling and the DNA damage response in organogenesis-stage mouse embryos. Toxicol. Sci. 133, 298-308.
2. Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., and Sanders, K. (2007). Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer J. Int. Cancer 121, 1138-1148.
3. Bell, D. M., Leung, K. K., Wheatley, S. C., Ng, L. J., Zhou, S., Ling, K. W., Sham, M. H., Koopman, P., Tam, P. P., and Cheah, K. S. (1997). SOX9 directly regulates the type-II collagen gene. Nat. Genet. 16, 174-178.
4. Bigaeva, E., Paradis, F. H., Moquin, A., Hales, B. F., and Maysinger, D. (2015). Assessment of the developmental toxicity of nanoparticles in an ex vivo 3D model, the murine limb bud culture system. Nanotoxicology. 9, 780-791.
5. Blander, G., and Guarente, L. (2004). The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417-435.
6. Bradley, E. W., McGee-Lawrence, M. E., and Westendorf, J. J. (2011). HDAC-mediated control of endochondral and intramembranous ossification. Crit. Rev. Eukaryot. Gene Expr. 21, 101-113.
7. Cairns, D. M., Liu, R., Sen, M., Canner, J. P., Schindeler, A., Little, D. G., and Zeng, L. (2012). Interplay of Nkx3.2, Sox9 and Pax3 regulates chondrogenic differentiation of muscle progenitor cells. PloS One 7, e39642.
8. Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., and Olson, E. N. (2006). Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126, 321-334.
9. Chiara, B., Ilaria, C., Antonietta, C., Francesca, C., Marco, M., Lucia, A., and Gilda, C. (2014). SIRT1 inhibition affects angiogenic properties of human MSCs. BioMed Res. Int. 2014, 783459.
10. Di Renzo, F., Broccia, M. L., Giavini, E., and Menegola, E. (2010). VPA-related axial skeletal defects and apoptosis: A proposed event cascade. Reprod. Toxicol. 29, 106-112.
11. Ding, M., Lu, Y., Abbassi, S., Li, F., Li, X., Song, Y., Geoffroy, V., Im, H. J., and Zheng, Q. (2012). Targeting Runx2 expression in hypertrophic chondrocytes impairs endochondral ossification during early skeletal development. J. Cell. Physiol. 227, 3446-3456.
12. Duvic, M., and Vu, J. (2007). Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics 1, 377-392.
13. Finkel, T., Deng, C. X., and Mostoslavsky, R. (2009). Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591.
14. Gabay, O., Zaal, K. J., Sanchez, C., Dvir-Ginzberg, M., Gagarina, V., Song, Y., He, X. H., and McBurney, M. W. (2013). Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone Spine Revue du Rhumatisme 80, 613-620.
15. Giavini, E., and Menegola, E. (2014). Teratogenic activity of HDAC inhibitors. Curr. Pharm. Des. 20, 5438-5442.
16. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G., et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978.
17. Jeon, E. J., Lee, K. Y., Choi, N. S., Lee, M. H., Kim, H. N., Jin, Y. H., Ryoo, H. M., Choi, J. Y., Yoshida, M., Nishino, N., et al. (2006). Bone morphogenetic protein-2 stimulates Runx2 acetylation. J. Biol. Chem. 281, 16502-16511.
18. Karsenty, G., and Park, R. W. (1995). Regulation of type I collagen genes expression. Int. Rev. Immunol. 12, 177-185.
19. Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., and Brosch, G. (2005). Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. J. Med. Chem. 48, 3344-3353.
20. Maye, P., Fu, Y., Butler, D. L., Chokalingam, K., Liu, Y., Floret, J., Stover, M. L., Wenstrup, R., Jiang, X., Gooch, C., et al. (2011). Generation and characterization of Col10a1-mcherry reporter mice. Genesis 49, 410-418.
21. Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., and Olson, E. N. (2007). Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21, 1790-1802.
22. Montgomery, R. L., Potthoff, M. J., Haberland, M., Qi, X., Matsuzaki, S., Humphries, K. M., Richardson, J. A., Bassel-Duby, R., and Olson, E. N. (2008). Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J. Clin. Invest. 118, 3588-3597.
23. Murko, C., Lagger, S., Steiner, M., Seiser, C., Schoefer, C., and Pusch, O. (2013). Histone deacetylase inhibitor Trichostatin A induces neural tube defects and promotes neural crest specification in the chicken neural tube. Differentiation 85, 55-66.
24. Neubert, D., and Barrach, H.-J. (1977). Techniques applicable to study morphogenetic differentiation of limb buds in organ culture. In Methods in Pre-Natal Toxicology (D. Neubert, H.-J. Merker, and T. Kwasigroch, Eds.), pp. 241-251. Georg Thieme, Stuttgart.
25. Ortega, N., Behonick, D., Stickens, D., and Werb, Z. (2003). How proteases regulate bone morphogenesis. Ann. N. Y. Acad. Sci. 995, 109-116.
26. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., Volk, C. B., Maxwell, M. M., Rochet, J. C., McLean, P. J., et al. (2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519.
27. Paradis, F. H., and Hales, B. F. (2013). Exposure to valproic acid inhibits chondrogenesis and osteogenesis in mid-organogenesis mouse limbs. Toxicol. Sci. 131, 234-241.
28. Paradis, F. H., and Hales, B. F. (2015). Valproic acid induces the hyperacetylation of P53, the expression of P53 target genes and markers of the intrinsic apoptotic pathway in mid-organogenesis murine limbs. Birth Defects Res. B Dev. Reprod. Toxicol. In press. doi: 10.1002/bdrb.21149.
29. Paradis, F. H., Huang, C., and Hales, B. F. (2012). The murine limb bud in culture as an in vitro teratogenicity test system. Methods Mol. Biol. 889, 197-213.
30. Poljak, M., Lim, R., Barker, G., and Lappas, M. (2014). Class I to III histone deacetylases differentially regulate inflammationinduced matrix metalloproteinase 9 expression in primary amnion cells. Reprod. Sci. 21, 804-813.
31. Razidlo, D. F., Whitney, T. J., Casper, M. E., McGee-Lawrence, M. E., Stensgard, B. A., Li, X., Secreto, F. J., Knutson, S. K., Hiebert, S. W., and Westendorf, J. J. (2010). Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PloS One 5, e11492.
32. Rigueur, D., Brugger, S., Anbarchian, T., Kim, J. K., Lee, Y. J., and Lyons, K. (2015). The type I BMP receptor ACVR1/ALK2 is required for chondrogenesis during development. J. Bone Miner. Res. 30, 733-741.
33. Schlisser, A. E., and Hales, B. F. (2013). Deprenyl enhances the teratogenicity of hydroxyurea in organogenesis stage mouse embryos. Toxicol. Sci. 134, 391-399.
34. Taunton, J., Hassig, C. A., and Schreiber, S. L. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411.
35. Thiagalingam, S., Cheng, K. H., Lee, H. J., Mineva, N., Thiagalingam, A., and Ponte, J. F. (2003). Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann. N. Y. Acad. Sci. 983, 84-100.
36. Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004). Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119, 555-566.
37. Villalba, J. M., and Alcain, F. J. (2012). Sirtuin activators and inhibitors. BioFactors 38, 349-359.
38. West, A. C., and Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30-39.
39. Yang, X. J., and Seto, E. (2008). The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9, 206-218.